BRD4 and cancer: The rational design of JQ1 as a competitive inhibitor of Bromodomain Containing Protein 4 (BRD4) [19] opened the avenue for molecularly-targeted therapeutic agents geared towards epigenetic reader proteins with key roles in homeostasis and cancer [20].